絞り込み

16555

広告

Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital.

著者 Yamazaki-Nishioka M , Kogiku M , Noda M , Endo S , Takekawa M , Kishi H , Ota M , Notsu Y , Shimizu M , Yamazaki H
Xenobiotica.2018 Sep 14 ; ():1-20.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (52view , 0users)

Full Text Sources

1. Steady-state plasma concentrations of anticoagulants and the time since the previous administration in mainly outpatients with atrial fibrillation administered standard or reduced doses were analyzed for 110 elderly Japanese subjects (mean age, 76 years) treated with apixaban (2.5 or 5.0 mg twice daily), dabigatran etexilate (110 or 150 mg twice daily), edoxaban (30 or 60 mg once daily), or rivaroxaban (10 or 15 mg once daily) at one general hospital. 2. The pharmacokinetics in patients treated with standard and reduced doses of the four anticoagulants using liquid chromatography-tandem mass spectrometry were compared with the concentration ranges estimated using physiologically based pharmacokinetic modelling. Reduced doses of anticoagulants resulted in relatively small pharmacokinetic variations compared with the standard dose. 3. Statistical analyses revealed that renal impairment is likely not the sole determinant factor for high plasma concentrations of apixaban, dabigatran, edoxaban, and rivaroxaban. 4. Patients with atrial fibrillation should be treated with the correct doses of oral anticoagulants as specified in the package inserts (e.g., reduced doses for elderly patients, patients with low body weights, and in combination with P-glycoprotein inhibitor drugs) to avoid excessive or insufficient doses of direct oral anticoagulants.
PMID: 30216091 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード